BELLEROPHON THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0567 USD | +0.71% |
|
+0.89% | +53.24% |
| May. 02 | North American Morning Briefing : Stock Futures -2- | DJ |
| Apr. 25 | North American Morning Briefing : More Tech -2- | DJ |
Presentation Operator MessageOperator (Operator)Greetings, and welcome to the Bellerophon Ther...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Companyâs focus is to develop its nitric oxide therapy for patients with pulmonary hypertension (PH) using its delivery system, INOpulse. The Companyâs INOpulse program is an extension of the technology used in hospitals to deliver continuous flow inhaled nitric oxide. INOpulse program is built on scientific and technical development for the therapeutic delivery of inhaled nitric oxide. It is also developing INOpulse for the treatment of patients with fibrotic interstitial lung disease (fILD), PH-Sarcoidosis, PH-chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension, and other pulmonary hypertension conditions. The Companyâs subsidiaries include Bellerophon BCM LLC, Bellerophon Pulse Technologies LLC and Bellerophon Services, Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.0567
Average target price
-
| 1st Jan change | Capi. | |
|---|---|---|
| +53.24% | 694K | |
| +8.29% | 114B | |
| +10.21% | 104B | |
| -11.90% | 22.41B | |
| +0.38% | 22.28B | |
| -5.48% | 19.07B | |
| -37.36% | 18B | |
| -5.17% | 17.89B | |
| +7.70% | 14.28B | |
| +37.65% | 12.55B |
- Stock Market
- Equities
- BLPH Stock
- News Bellerophon Therapeutics, Inc.
- Transcript : Bellerophon Therapeutics, Inc. - Special Call